MAP2K7 and melanoma: However, NRAS-mutant melanoma currently lacks effective targeted therapies, and targeting the pro-survival pathways downstream of oncogenic NRAS (e.g., PI3K or MEK inhibitors) have not been successful (Britten, 2013; Samatar and Poulikakos, 2014; Zhao and Adjei, 2014).